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Abstract. To investigate the association of MMP7 and VEGF expression with ovarian 
cancer, benign ovarian cysts, and normal ovaries. This study was analytical research with 
case-control design. In the study, IHC expression of MMP7 and VEGF was carried out on 
paraffin block of ovarian cancer tissue, benign ovarian cyst, and normal ovary. In 40 subjects 
with ovarian tumors, 17 patients were found with positive MMP7 expression. In the control 
group, no subjects were found with positive MMP7 expression. There was a significant 
relationship between MMP7 expression and ovarian tumor incidence. Meanwhile, in 40 
subjects with ovarian tumors, 21 patients were found with positive VEGF expression. In the 
control group, no subjects with positive VEGF expression were found. There was a 
significant relationship between VEGF expression and ovarian tumor incidence. There was 
a significant relationship between MMP7 and VEGF expression with ovarian tumor 
incidence. 
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Abstrak. Untuk menyelidiki asosiasi ekspresi MMP7 dan VEGF dengan kanker ovarium, 
kista ovarium jinak, dan ovarium normal. Penelitian ini merupakan penelitian analitik 
dengan desain case control. Dalam penelitian, ekspresi IHC MMP7 dan VEGF dilakukan 
pada blok parafin dari jaringan kanker ovarium, kista ovarium jinak, dan ovarium normal. 
Pada 40 subjek dengan tumor ovarium, 17 pasien ditemukan dengan ekspresi MMP7 positif. 
Dalam kelompok kontrol, tidak ada subjek yang ditemukan dengan ekspresi MMP7 positif. 
Ada hubungan yang signifikan antara ekspresi MMP7 dan kejadian tumor ovarium. 
Sementara itu, di 40 subjek dengan tumor ovarium, 21 pasien ditemukan dengan ekspresi 
VEGF positif. Dalam kelompok kontrol, tidak ada subjek dengan ekspresi VEGF positif yang 
ditemukan. Ada hubungan yang signifikan antara ekspresi VEGF dan kejadian tumor 
ovarium. Ada hubungan yang signifikan antara MMP7 dan ekspresi VEGF dengan kejadian 
tumor ovarium. 
Kata Kunci: Ovarium Normal, Kista Ovarium jinak, Kanker ovarium, MMP7, VEGF 
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1. Introduction 
Ovarian cancer is the fifth leading cause of cancer in women by 2014, according to the National 
Cancer Institute (NCI). Statistically, in the United States, ovarian cancer is diagnosed in 22,000 
women and cause 14,000 deaths every year [1]. 
In Indonesia, based on Center for Data and Information Kementerian Kesehatan RI 2015, 
prevalence of ovarian cancer in Dharmais Hospital for 4 years was 113 big cases and 22 death 
cases in 2010, 146 new case and 31 death case in 2011, 144 new case and 27 death case in 2012, 
134 new case and 46 death case in 2013 [2]. 
The number of ovarian cysts in RSUP Haji Adam Malik Medan from January 2012 to December 
2013 was 120 cases. The prevalence of ovarian cysts on all occurrences of ovarian tumors in Haji 
Adam Malik General Hospital Medan in 2012 - 2013 was 12.18% [3]. In RSU Dr. Pirngadi Medan 
from January to October 2010, there were 34 people with ovarian cysts in women of childbearing 
age [4]. 
The growth of tumors and metastases depends on angiogenesis and lymphogenesis by chemical 
signals originating from tumor cells at a rapid growth stage. Cancer cells that do not have blood 
flow grow to 1 - 2mm2 and stop at 2 mm in diameter. When the tumor grows to a diameter of a 
few millimeters, the hypoxia and loss of nutrients cause the tumor microenvironment to release 
an "angiogenic switch" signal to allow tumor growth [5]. 
MMP is an extracellular proteinase family that targets various ECM proteins. They are involved 
in the angiogenesis process by breaking the perivascular ECM and liberating the angiogenic factor 
from ECM. MMP7 is mainly expressed by cancer cells. Therefore, MMP7 acts as a specific signal 
of cancer cells in the stromal cell component necessary for tumor angiogenesis [6]. 
VEGF is the main regulator of angiogenesis that promotes cell survival, proliferation, and 
endothelial cell migration while increasing vascular permeability. Basically, by increasing tumor 
angiogenesis and increasing vascular permeability, VEGF contributes to the occurrence of 
peritoneal carcinomatosis associated with malignant ascites formation, which is characteristic of 
the diagnosis of advanced ovarian cancer [7]. 
From this background, researchers are interested to investigate the contribution of MMP7 and 
VEGF on the development of ovarian tumors by performing immune histochemical tests in three 
groups: normal ovaries, benign ovarian cysts, and ovarian cancer. 
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2. Methodology 
This study was analytical research with case-control design. In the study, immune histochemical 
expression of MMP7 and VEGF was carried out on paraffin block of ovarian cancer tissue, benign 
ovarian cyst, and normal ovary. 
The sample was part of the study population that had a paraffin block biopsy of ovarian cancer 
tissue, benign ovarian cyst, and normal ovaries stored in Anatomical Pathology Laboratory of 
RSUP H. Ad-am Malik Medan. Subjects were paraffin blocks of ovarian cancer tissue and benign 
ovarian cysts obtained from patients who had undergone gynecological and oncology surgery at 
RSUP HAM and had been confirmed at Anatomical Pathology Laboratory of FK USU.  
While the control group study subjects were nor-mal ovarian tissue paraffin blocks obtained from 
non-ovarian cyst gynecologic surgery that had previously been confirmed from laboratory results 
of Anatomical Pathology of FK USU. 
3. Result 
Table 1. Characteristic of Demographies 
Demography Characteristics 
Malignant 
Tumor (n=20) 
Benign Tumor 
(n=20) 
Normal 
(n=20) 
Age, mean (SD), year 50,25 (9,83) 37,55 (10,50) 51,55 
(5,20) 
BMI, mean (SD), kg/cm2 22,27 (1,06) 24,48 (2,91) 23,55 
(2,41) 
Menarche, mean (SD), year 11,4  
(1,35) 
11,35 (1,50) 11,95 
(1,19) 
Pregnancy status, n (%)    
   Nullipara  10 (50) 5 (25) 0 
   Primigravida 6 (30) 3 (15) 0 
   Multigravida  4 (20) 12 (60) 20 (100) 
Menopause, n (%)    
   Not yet  7 (35) 17 (85) 7 (35) 
   Already 13 (65) 3 (15) 13 (65) 
 
 
 
 
 
 
Sumatera Medical Journal (SUMEJ) Vol. 02, No. 08, 2018                                                            4 
Table 2. Histopathologic Distribution based on Ovarian Malignancy 
Histopathologic Findings n (%) 
Malignant Tumor  
Adenocarcinoma 
mucinosum 
11 (55) 
Adenocarcinoma 
Serosum 
8 (40) 
Endometrioid 
carcinoma 
1 (5) 
Benign Tumor  
Cysadenoma 
musinosum 
6 (30) 
Dermoid cycst 5 (25) 
Endometriosis cycst 3 (15) 
Cysadenoma serosum 6 (30) 
 
Based on the results of the histopathological examination, the most common malignant type was 
Adenocarcinoma mucinosum of 11 people (55%), followed by Adenocarcinoma serosum of 8 
people (40%) and Endometrioid carcinoma of 1 person (5%). In benign tumors, most types of 
tumors are Cystadenoma musinosum and serosum as many as six people (30%). Dermoid cysts 
were found in 5 subjects (25%). And, endometriosis cysts are present in 3 subjects (15%). 
Table 3. Expression of MMP7 based on Ovarian Tumor Type 
 
Malignant 
Tumor 
Benign 
Tumor 
Normal 
MMP7 Expression    
   Strong 3 (15) 2 (10) 0 
   Medium  4 (20) 0 0 
   Mild  7 (35) 1 (5) 0 
   Negative  6 (30) 17 (85) 20 
(100) 
VEGF Expression    
   Strong 4(20) 1 (5) 0 
   Medium 7 (35) 0 0 
   Mild 2 (10) 7 (35) 0 
   Negative  7 (35) 12 (60) 20 
(100) 
The results showed that MMP7 expression with the strongest level of malignant tumor was three 
people (15%) and in the benign tumor, the group was only two people (10%). Meanwhile, no 
strong MMP7 expression was found in subjects with normal ovaries. Negative MMP7 expression 
in malignant tumors was found in 6 patients (30%), whereas in the group of benign tumors were 
present in 17 people (85%), and in subjects, with normal ovaries, no MMP7 expression was found. 
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Table 4. Relationship of MMP7 Expression and VEGF with Ovarian Tumor 
 
Ovarian 
Tumor 
(n=40) 
Normal/Control 
(n=20) 
p* 
MMP7 Expression    
 Positive    17 (42, 
5) 
0 <0,001 
 Negative    23 
(57,5) 
20 (100)  
VEGF Expression    
 Positive    21 (65) 0 <0,001 
       Negative    19 (35) 20 (100)  
                                     Fisher’s Exact 
From 40 subjects with ovarian tumors, 17 patients (42.5%) were found with positive MMP7 
expression. In the control group, no subjects were found with positive MMP7 expression. Using 
Fisher's exact test, there was a significant relationship between MMP7 expression and ovarian 
tumor incidence (p <0.001). 
Meanwhile, from 40 subjects with ovarian tumors, 21 patients (65%) were found with positive 
VEGF expression. In the control group, no subjects with positive VEGF expression were found. 
Using Fisher's exact test, there was a significant relationship between VEGF expression and 
ovarian tumor incidence (p <0.001). 
4. Discussion 
Table 1 shows that the mean age of subjects with malignant tumors was 50.25 years, in benign 
tumor group was 37.55 years, and mean age in control group was 51.55 years. The risk of 
developing ovarian cancer increases with age. Ovarian cancer is rare at the age of fewer than 40 
years. Most often suffered by menopausal women. Incidence begins and increases from the age 
of 40 years and 80-84 years. The average occurred at age 63 years, 48% died at the age of 65 
years or older [7], [8].   
From the number of parities, in the group of malignant tumors, there were ten people (50%), 
nullipara, whereas in the group of benign tumors there were five people (25%) and no nullipara 
in the control group. The cause of ovarian cysts can be a normal physiological process to a genetic 
mutation involving a tumor suppressor and growth. Risk factors for ovarian cysts and ovarian 
cancer include nulliparity (never give birth) and low parity. Several studies have shown that 
women of parity are estimated to have a 30-60% lower risk for the occurrence of ovarian cancer 
[3], [4]. 
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A study in Albania found a strong association between nulliparous women and the risk of ovarian 
cancer. Nulliparous women have a risk of 12.5 times higher than female parity [5]. 
Table 3 shows that MMP7 expression with the highest level of strongest in the malignant tumor 
as much as three people (15%) and in benign tumor group only as much as two people (10%). 
Meanwhile, no strong MMP7 expression was found in subjects with normal ovaries. Negative 
MMP7 expression in malignant tumors was found in 6 patients (30%), whereas in the group of 
benign tumors were present in 17 people (85%), and in subjects, with normal ovaries, no MMP7 
expression was found. 
Particularly, MMP7 has been shown to increase in 80% of malignant human ovarian cancers 
compared with 40% in normal or benign samples. MMP7 has also been shown to be expressed in 
stromal ovarian cancer tissue especially in serous cancers. Polymorphism in the MMP7 promoter 
region has shown that single nucleotide polymorphisms in MMP7 are significantly higher in 
ovarian cancer patients than in controls. Also, MMP7 serum levels were higher in patients with 
serous and musinous ovarian cancers compared with controls [9].  
Based on VEGF measurements, it was found that VEGF expression with the highest level was 
found in the subjects group with four malignant tumors (20%), whereas in subjects with the 
benign tumor, only one person (5%). Negative expression in the malignant tumor group was also 
found in 7 patients. 
A study conducted in Philadelphia found that malignant neoplasms have a VEGF level 24 times 
higher than benign cysts and six times higher than borderline lesions. VEGF levels in malignant 
tumors are about 7.3 - 97.5 ng / ml while in non-aligned lesions between undetectable to very 
low. VEGF levels in borderline lesions are three times higher than benign lesions [5]. 
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